Behold the Boxer
The dog genome project researchers at the Whitehead/MIT Center for Genome Research are readying to unleash their sequencers in June, and have chosen the boxer as the best of breed after analyzing 120 dogs in 60 breeds. The dog genome is expected to be useful in studies of genetic disease including blindness, deafness, cancer, heart disease, and autoimmune disorders.
Find “Dog Genome Sequencers to Begin ‘Ruff’ Draft of Boxer Breed: Chimp, Honeybee Almost Sequenced” by searching: boxer
Genomic Solutions, a subsidiary of Harvard Bioscience, has settled a lawsuit brought in December by Oxford Gene Technology and said it is evaluating whether to appeal a $1.45 million judgment against it in a breach of contract suit brought by Affymetrix in a Michigan court. Regardless, the company has exited the business of selling pre-printed microarrays.
Find “Genomic Solutions Settles with Oxford Gene Technology” by searching: Oxford
“One of the great things about this institution is that there is no medical school and zero temptation to mix medicine with science.”
— David Botstein at the opening of the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where he will assume directorship in July
Find “Microarray Pioneer David Botstein Opens Integrative Genomics Center at Princeton” by searching: Botstein
IBM doesn’t refer to its newest life science initiative as “information-based medicine” for nothing. Joe Jasinski, worldwide operations manager for life sciences, quipped that it would be just fine with Big Blue if the term’s acronym — which is (ahem) IBM — happens to find its way into common parlance. After all, his company is planning to provide the IT infrastructure that would make such a vision possible.
Find “IBM Exec: Research Partnerships Are Pieces of the Information-Based Medicine Puzzle” by searching: puzzle
Almost five months after Structural Bioinformatics and GeneFormatics said they were going to merge, their new identity has been revealed: the two companies became Cengent Therapeutics. With a reduced headcount, a cushion of cash, a broader range of computational and experimental technologies than either company had, and a new emphasis on internal drug discovery, the company hopes to better weather the unfavorable current economic climate.
Find “SBI and GFI Become Cengent; Focus on Proteomics Services, Drug Discovery” by searching: Cengent
Slowdown to Market
Certain “market-preparation” setbacks, including pricing concerns, mean Affymetrix and Roche''s AmpliChip cytochrome P450 multi-analyte diagnostic will roll out at the end of June instead of late May, according to a senior Roche official.
Find "Marketing Setbacks Force Roche and Affymetrix to Delay AmpliChip Launch" by searching: AmpliChip